Brokerages expect Radius Health Inc (NASDAQ:RDUS) to announce earnings of ($0.81) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Radius Health’s earnings. The highest EPS estimate is ($0.69) and the lowest is ($0.98). Radius Health reported earnings of ($0.85) per share in the same quarter last year, which would suggest a positive year over year growth rate of 4.7%. The firm is expected to issue its next earnings results on Thursday, November 7th.
According to Zacks, analysts expect that Radius Health will report full year earnings of ($3.36) per share for the current financial year, with EPS estimates ranging from ($3.85) to ($2.98). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.65) per share, with EPS estimates ranging from ($3.51) to ($1.75). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Radius Health.
Radius Health (NASDAQ:RDUS) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.09. Radius Health had a negative net margin of 127.22% and a negative return on equity of 368.58%. The firm had revenue of $41.04 million for the quarter, compared to analyst estimates of $40.60 million. During the same quarter last year, the business posted ($0.99) earnings per share. The company’s quarterly revenue was up 81.4% on a year-over-year basis.
Radius Health stock traded down $0.20 during mid-day trading on Friday, reaching $23.67. The company had a trading volume of 316,570 shares, compared to its average volume of 408,286. Radius Health has a fifty-two week low of $12.81 and a fifty-two week high of $25.40. The company has a current ratio of 4.38, a quick ratio of 4.28 and a debt-to-equity ratio of 6.75. The company has a market cap of $1.10 billion, a P/E ratio of -4.85 and a beta of 0.95. The business has a fifty day simple moving average of $22.53 and a 200 day simple moving average of $21.28.
In related news, Director Anthony Rosenberg sold 1,584 shares of Radius Health stock in a transaction on Monday, July 1st. The shares were sold at an average price of $24.60, for a total transaction of $38,966.40. Following the completion of the transaction, the director now owns 8,716 shares of the company’s stock, valued at $214,413.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Joseph Francis Kelly bought 2,500 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were purchased at an average cost of $21.81 per share, with a total value of $54,525.00. Following the purchase, the vice president now directly owns 7,500 shares of the company’s stock, valued at $163,575. The disclosure for this purchase can be found here. 4.00% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its stake in Radius Health by 51.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,875,313 shares of the biopharmaceutical company’s stock worth $94,403,000 after buying an additional 1,314,899 shares during the last quarter. Eversept Partners LP grew its position in Radius Health by 10.1% in the 2nd quarter. Eversept Partners LP now owns 710,517 shares of the biopharmaceutical company’s stock valued at $17,308,000 after acquiring an additional 65,100 shares in the last quarter. Artisan Partners Limited Partnership grew its position in Radius Health by 1.1% in the 1st quarter. Artisan Partners Limited Partnership now owns 705,574 shares of the biopharmaceutical company’s stock valued at $14,069,000 after acquiring an additional 7,872 shares in the last quarter. Spark Investment Management LLC grew its position in Radius Health by 15.5% in the 1st quarter. Spark Investment Management LLC now owns 677,800 shares of the biopharmaceutical company’s stock valued at $13,515,000 after acquiring an additional 91,200 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in Radius Health by 596.4% in the 2nd quarter. Emerald Advisers LLC now owns 662,113 shares of the biopharmaceutical company’s stock valued at $16,129,000 after acquiring an additional 567,038 shares in the last quarter.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Recommended Story: What does the Producer Price Index (PPI) tell investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.